Sandoz says new clinical data support two biosimilars
November 14, 2017 at 02:14 AM EST
ZURICH, Nov 14 (Reuters) - Novartis' generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.
